Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Updates are required to stay supported. Please upgrade to Microsoft 365 to get product support. Install Microsoft 365 on your Mac, PC, tablets, and phones. With full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback